MedPath

Chengdu Easton Biopharmaceuticals Co.,Ltd

Ownership
-
Established
2009-06-01
Employees
1.4K
Market Cap
-
Website
www.eastonpharma.cn
Introduction

The company is a high-tech enterprise driven by R&D and innovation, integrating R&D, production and sales of chemical raw materials, high-end chemicals and biopharmaceuticals. The company was founded in 2009, has 8 wholly-owned subsidiaries, and currently employs more than 1,400 people. The company was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange in September 2020. The company is a high-tech enterprise, driven by R&D and innovation, integrating the entire R&D, production and sales industry chain of chemical raw materials, high-end chemicals and biopharmaceuticals. The company's main products include high-end chemicals, small molecule innovative drugs, biopharmaceuticals, and APIs. Company honors: Sichuan Province Intellectual Property Strong Enterprise Cultivating Enterprise, 2022 Sichuan Health Industry Outstanding Enterprise, 2022 Sichuan Enterprise Top 20 Enterprise with the Most Potential for Technological Innovation and Development, 2022 Top 100 Sichuan Enterprises with Invention Patents, 2022 Best Industrial Enterprise in China Pharmaceutical R&D Product Line, 2022 Honorary Title of “Quality Craftsman Enterprise” in the Chinese Pharmaceutical Industry, “National Technological Innovation Demonstration Enterprise” and “National Green Factory”, “2022 China's Top 100 Pharmaceutical Innovation Enterprises”, etc.

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

76

NMPA:76

Drug Approvals

Apalutamide Tablets

Product Name
阿帕他胺片
Approval Number
国药准字H20254353
Approval Date
May 27, 2025
NMPA

Oxazepam Tablets

Product Name
奥沙西泮片
Approval Number
国药准字H20254336
Approval Date
May 27, 2025
NMPA

Axitinib Tablets

Product Name
阿昔替尼片
Approval Number
国药准字H20254331
Approval Date
May 27, 2025
NMPA

Dacomitinib Tablets

Product Name
达可替尼片
Approval Number
国药准字H20254222
Approval Date
May 20, 2025
NMPA

Dacomitinib Tablets

Product Name
达可替尼片
Approval Number
国药准字H20254223
Approval Date
May 20, 2025
NMPA

Diprophylline Injection

Product Name
二羟丙茶碱注射液
Approval Number
国药准字H20253579
Approval Date
Mar 11, 2025
NMPA

Bumetanide Injection

Product Name
布美他尼注射液
Approval Number
国药准字H20253233
Approval Date
Jan 24, 2025
NMPA

Vecuronium Bromide for Injection

Product Name
注射用维库溴铵
Approval Number
国药准字H20253159
Approval Date
Jan 14, 2025
NMPA

Ruxolitinib Phosphate Tablets

Product Name
磷酸芦可替尼片
Approval Number
国药准字H20249398
Approval Date
Nov 15, 2024
NMPA

Compound Glycyrrhizin Tablets

Product Name
复方甘草酸苷片
Approval Number
国药准字H20244585
Approval Date
Jul 30, 2024
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 8
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.